Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quetiapine + vitamin B12 is a combination therapy involving quetiapine, an atypical antipsychotic, and vitamin B12 (cobalamin), a water-soluble vitamin essential for neurological function and hematopoiesis. Quetiapine acts primarily as an antagonist at serotonin 5-HT2A and dopamine D2 receptors, stabilizing mood and reducing psychotic symptoms in conditions such as schizophrenia, bipolar disorder, and major depressive disorder. Vitamin B12 is crucial for DNA synthesis, myelin formation, and cellular metabolism. In clinical studies involving patients with Alzheimer's disease (AD) experiencing psychosis or pain symptoms, the addition of vitamin B12 to quetiapine therapy resulted in improved psychiatric outcomes (notably on the Brief Psychiatric Rating Scale), reduced pain scores, modulation of pro- and anti-inflammatory cytokines (decreased IL-8/TNF-α; increased TGF-β), and enhanced cognitive measures compared to quetiapine alone[1][2][9]. This suggests that the combination may offer synergistic benefits in neuropsychiatric disorders where inflammation or neuropathic pain are present.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quetiapine + vitamin B12.